Results 61 to 70 of about 46,038 (143)

Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study. [PDF]

Inflamm Bowel Dis
Boute EH, Gianolio L, Mahmmod S, Pochesci S, Armstrong K, Henderson P, Wilson DC, de Ridder L, Russell RK, Escher JC.   +9 more
europepmc   +1 more source

Week 14 Infliximab Level Provides Modest Benefit to Clinical Outcomes in Children with Crohn's Disease. [PDF]

Pediatr Gastroenterol Hepatol Nutr
Jois A, Horn R, Walia A, Little RD, Alex G.   +4 more
europepmc   +1 more source

Cutaneous Leukocytoclastic Vasculitis as a rare adverse event of infliximab in Crohn's disease: a case report. [PDF]

Oxf Med Case Reports
El Mourad H, Alsayed E, Al Doheyan T, Alomar Y, Alharbi O.   +4 more
europepmc   +1 more source

A Systematic Review of Literature: TNF-α Blockers and JAK Inhibitors for the Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Severe Forms of Erythema Multiforme. [PDF]

Health Sci Rep
Salehi S, Torabi P, Abbaspour M, Hajizadeh N, Sadeghi S, Jafarzadeh A, Goodarzi A.   +6 more
europepmc   +1 more source

Is Routine Monitoring of TNF-α Inhibitor Levels and Antibodies in Pediatric IBD Justified in the Era of Personalized Medicine. [PDF]

J Clin Med
Pytrus T, Szyller HP, Augustynowicz G, Lasocka M, Watras S, Akutko K.   +5 more
europepmc   +1 more source

A Comparative Study of Different Biological Drugs in First-Line Therapy in Crohn's Disease: A Multicenter Descriptive Analysis. [PDF]

Medicina (Kaunas)
Gila A, Preda CM, Diculescu M, Bratu RM, Istratescu D, Stroie T, Trifan A, Tantau A, Bucurica S, Tieranu CG, Minea H, Buzuleac AM, Negreanu L, Popescu R, Ciora CA.   +14 more
europepmc   +1 more source

Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar. [PDF]

Clin Med Insights Arthritis Musculoskelet Disord
Shakur AA, Kumar R, Ranjan RK, Hameed S, Mohan L.   +4 more
europepmc   +1 more source

Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database. [PDF]

Proc (Bayl Univ Med Cent)
Almusabeh H, Alzaher M, Vaughan M, Teran D, Kovac Z, Adeniran O, Shepherd K, Elfert K, Goswami S, Hadam-Veverka J, Tandon K.   +10 more
europepmc   +1 more source

On the heartbreak of anti-tumor necrosis factor drugs. [PDF]

Proc (Bayl Univ Med Cent)
Schiller L.
europepmc   +1 more source

Infliximab-associated multifocal central nervous system demyelination mimicking multiple sclerosis in a patient with Crohn's disease: a case report. [PDF]

BMC Neurol
Sawaftah MA, AbuBaha M, AbuBaha B, Shoman M, Muneeb Izzat Abbas M.   +4 more
europepmc   +1 more source